


A Guide to Pressure Injury Prevention and Treatment

Smith+Nephew







Stages in pressure injuries



STAGE 1

Intact skin with a localized area of non-blanchable erythema; may appear differently in darkly pigmented skin




STAGE 2

- Partial-thickness loss of skin with exposed dermis
- Wound bed is viable, pink or red, moist, and may also present as an intact or ruptured serum-filled blister
- Adipose (fat) and/or deeper tissues are not visible
- Granulation tissue, slough and eschar are not present




STAGE 3

- Full-thickness loss of skin, in which adipose (fat) is visible in the ulcer and granulation tissue and epibole (rolled wound edges) are often present.
- Slough and/or eschar may be visible.




STAGE 4

Full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage or bone in the ulcer.



UNSTAGEABLE


Full-thickness skin and tissue loss in which the extent of tissue damage within the ulcer cannot be confirmed because it is obscured by slough or eschar.



Stages in pressure injuries


DEEP TISSUE INJURY

- Intact or non-intact skin with localized area of persistent non-blanchable deep red, maroon, purple discoloration, or epidermal separation revealing a dark wound bed or blood-filled blister.
- Discoloration may appear differently in darkly pigmented skin.



MUCOSAL MEMBRANE PRESSURE INJURY

Mucosal membrane pressure injury is found on mucous membranes with a history of a medical device in use at the location of the injury. These ulcers cannot be staged.



MEDICAL DEVICE-RELATED PRESSURE INJURY

DEFINITION

- Results from the use of devices designed and applied for diagnostic or therapeutic purposes.
- The resultant pressure injury generally conforms to the pattern or shape of the device.
- The injury should be staged/graded according to the pressure ulcer/injury classification system.



Preventive skin care starts with good skin hygiene

Cleanse the skin¹

- Keep skin clean especially after episode of incontinence
- Avoid using alkaline soaps and cleansers

Moisturize the skin with emollient¹

- Preserves the skin's barrier function

Apply skin protectant¹

- Provides a barrier to penetration by water, urine, stool and associated irritants

SECURA[◇]
Total Body Foam Cleanser
and Personal Cleanser

NO-STING SKIN-PREP[◇]
Skin Protectant

SECURA[◇]
Moisturisers

SECURA[◇]
Protectants

CLEANSE

MOISTURIZE

PROTECT



References:

1. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. Emily Haesler (Ed.). EPUAP/NPIAP/PPPIA: 2019.

2019 Guidelines for prophylactic dressing in Pressure Injury Prevention

“Use a soft silicone multi-layered foam dressing to protect the skin for individuals at risk of pressure injuries.”¹⁸

The ALLEVYN[◇] LIFE difference

- Unique five layers construction re-distribute pressure, reduce friction and shear.^{1,2}
- Improves dressing conformity and patient comfort^{3,4,5}
- Proven to reduce risk of pressure injury when used as part of pressure injury protocol⁶



ALLEVYN LIFE
Sacrum Dressing



ALLEVYN LIFE
Dressing



ALLEVYN LIFE
Heel Dressing

ALLEVYN[◇] GENTLE BORDER Foam Dressings

- ALLEVYN GENTLE BORDER Dressings are versatile, conformable and easy to cut,⁷⁻¹¹ making it ideal to protect skin under medical-devices
- The multi-way stretch helps application on awkward areas and joints^{7-9,11}



ALLEVYN
GENTLE BORDER
Square Dressing



ALLEVYN
GENTLE BORDER
Sacrum Dressing



ALLEVYN
GENTLE BORDER
Heel Dressing




ALLEVYN
GENTLE BORDER
Multiuse Dressing

ALLEVYN[◇] GENTLE BORDER LITE Dressings

ALLEVYN GENTLE BORDER LITE Dressings conform to the contours of the face^{12,13} and help protect skin exposed to pressure and friction.^{12,14-17}



ALLEVYN
GENTLE BORDER LITE
Square Dressing




ALLEVYN
GENTLE BORDER LITE
Rectangle Dressing

References:


1. Smith+Nephew 2018. Pressure Redistribution Testing of ALLEVYN LIFE vs Mepilex™ Border and Optifoam™ Gentle SA. Internal report. DS/18/351/R. 2. Smith+Nephew 2019. Properties of ALLEVYN LIFE advanced wound care dressing that can contribute to the effective use as part of a Pressure Injury Prevention protocol. Internal report. RD/19/177. 3. Rossington A, Drysdale K, Winter R. Clinical performance and positive impact on patient wellbeing of ALLEVYN LIFE. Wounds UK. 2013;9(4):91–95. 4. Stephen-Haynes J, Bielby A, Searle R. The clinical performance of a silicone foam in an NHS community trust. Journal of Community Nursing. 2013;27(5):50–59. 5. Simon D, Bielby A. A structured collaborative approach to appraise the clinical performance of a new product. Wounds UK. 2014;10(3):80–87. 6. Forni C, D’Alessandro F, Gallerani P, et al. Effectiveness of using a new polyurethane foam multi-layer dressing in the sacral area to prevent the onset of pressure ulcer in the elderly with hip fractures: A pragmatic randomised controlled trial. Int Wound J. 2018; 15(3):383–390. 7. Hurd T, Gregory L, Jones A, Brown S. A multi-centre in-market evaluation of ALLEVYN GENTLE BORDER. Wounds UK. 2009;5(3):32–44. 8. Smith & Nephew 2016. ALLEVYN GENTLE BORDER Heel Gen 2 - physical evaluation. Internal report. DS/16/465/R. 9. Smith & Nephew 2017. ALLEVYN GENTLE BORDER Gen 2 - Physical Evaluation. Internal report. DS/16/424/R V3. 10. Smith & Nephew 2015. Cutting of ALLEVYN variants. Internal report. DS/14/318/R. 11. Rafter L, Reynolds T, Rafter M. An audit of patient outcomes in the management of skin tears using silicone dressings. Wounds UK. 2016;12(2):70–78. 12. Smith+Nephew 2021. PMS 274 ALLEVYN Gentle Border Lite: PMCF ACTIVITY SUMMARY REPORT. Internal report. 13. Smith+Nephew 2010. ALLEVYN Gentle Border Lite Dressing Physical Properties. Internal report. DS/10/100/R1. 14. Smith+Nephew 2021. Pressure Redistribution Testing of Allevyn Gentle Border Lite. Internal report. DS/21/336/R. 15. Smith+Nephew 2021. Pressure Transmission of Face Mask over ALLEVYN Gentle Border and Mepilex™ Border Lite. Internal report. DS/21/274/R. 16. Smith+Nephew 2012. Friction Testing Comparison of ALLEVYN Gentle Border Lite versus other Competitor Products. Internal report. DS/11/125/R1. 17. Smith+Nephew 2019. Properties of ALLEVYN life advanced wound care dressing that can contribute to the effective use as part of a Pressure Injury Prevention protocol. Internal Report. RD/19/177. 18. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. Emily Haesler (Ed). EPUAP/NPIAP/PPPIA: 2019.

T.I.M.E. clinical decision support tool

START HERE ↓



D DECIDE appropriate treatment



E EVALUATE and reassess the treatment and wound management outcomes

Evaluate: Record wound progression within given timelines.
Flag if no change, go back to **A, B, C** and change treatment where indicated. Repeat pressure injury risk assessment as per your protocol.

†NPWT: Negative Pressure Wound Therapy. ‡ Level of exudate for wounds suitable for NPWT. § SECURA Range includes SECURA Moisturising Cleanser, SECURA Total Body Foam, SECURA Dimethicone Protectant, SECURA Extra Protective Cream, No Sting Skin Prep; PROSHIELD Range includes PROSHIELD Plus and PROSHIELD Foam and Spray. ∞ Biofilm wound care: Debridement, cleanse and use anti-biofilm agent. ++ Debride and cleanse and use effective topical antimicrobial as per local protocol.

References: 1. Schultz GS, et al. Wound Rep Reg (2003);11:1–28. 2. Leaper DJ, et al. Int Wound J 2012; 9 (Suppl. 2):1–19. 3. International Wound Infection Institute (IWII) Wound infection in clinical practice. Wounds International (2016). 4. Weir D, Schultz G. Assessment and Management of Wound-Related Infections. In Doughty D & McNichol L (Eds.). Wound, Ostomy and Continence Nurses Society Core Curriculum: Wound Management (p. 156–180). 2016. Philadelphia: Wolters-Kluwer. 5. Wolcott RD, et al. J Wound Care 2010;19(2):45–53. 6. Schultz G, et al. Wound Repair Regen 2017;25(5):744–757. 7. Ayello EA, et al. Wounds Int 2012;1–24. 8. Smith G, et al. Journal of Wound Care 2010;19(9):396–402. 9. Moore Z, et al. Journal of Wound Care, 2019;28(3):154–161. 10. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. Emily Haesler (Ed.) EPUAP/NPIAP/PPPIA. 2019. 11. Developed with the support of Glenn Smith⁸ and Moore et al. 2019⁹

The products used in the T.I.M.E. clinical decision support tool may vary in different markets. Not all products referred to may be approved for use or available in all markets. Please consult your local Smith+Nephew representative for further details on products available in your market.

T.I.M.E. Portfolio Solutions

INTRASITE[◇] GEL Hydrogel Wound Dressing

A non-adherent hydrogel that rehydrates necrotic tissue, promoting autolytic debridement.^{1-10,12,13,30}

Effective debridement and desloughing

Effective rehydrating action can produce rapid debridement of necrotic tissue^{3,6,20,21-26} whilst preserving the surrounding viable skin.^{5,9,11,18,19,27}

Easy application

The unique APPLIPAK[◇] system provides simple, directable and controlled application, even in awkward wound sites.^{1,2,6,9,12,13-18,28,29}



Autolytic debridement can be carried out by any clinician

Also available as INTRASITE Autolytic debridement can be carried out by any clinician.


Also available as INTRASITE CONFORMABLE Conformable Hydrogel Dressing

VERSAJET[◇] II Hydrosurgery System

VERSAJET reduces the need for radical wound excision, instead facilitating removal of necrosis and other unwanted material from the wound surface, thus preserving more viable tissue¹⁻³

Helps enable a surgeon to:

- Preserve viable tissue and reduce number of debridement procedures¹⁻³
- Effectively remove embedded contaminants¹⁻⁴
- Create a smooth wound bed which may enhance graft take⁵



ACTICOAT[®]

Antimicrobial Barrier Dressings

Our ACTICOAT range of dressings starts killing bacteria in as little as 30 minutes¹⁻⁴

With a sustained action of up to seven days for ACTICOAT 7 and ACTICOAT Flex7 dressings^{9,10,13,15}, and up to three days for ACTICOAT and ACTICOAT Flex 3.^{3,14}

- Fast acting¹⁻⁴
- Releases silver into the wound^{14-16,18} for infection¹⁻⁴
- Sustained action up to 3 or 7 days^{9,10,13-17}



IODOSORB[®]

0.9% Cadexomer Iodine Dressings



The unique dual action of IODOSORB is particularly effective in the disruption of biofilm:¹⁻⁷

1. High absorptive property

- Dehydration of the biofilm matrix²
- Desloughing action⁸⁻⁹
- Promotes autolytic debridement¹⁰

2. Antimicrobial 0.9% Iodine

- Killing the exposed biofilm bacteria²
- Sustained gentle release of iodine^{11,12}
- Broad spectrum antimicrobial efficacy¹³⁻¹⁵



T.I.M.E. Portfolio Solutions

ALLEVYN[◇] Foam Dressing

- Unique triple layer structure ensures optimal fluid handling for moist wound healing.¹
- Absorbent hydrocellular foam core absorbs excess fluid while maintaining a moist wound environment, which promotes faster wound healing.²⁻⁸
- High moisture vapour transmission top film, allows for transpiration of exudate. This top film is a barrier against bacteria including MRSA.⁹⁻¹¹
- Non-adherent wound contact layer allows friable granulation tissue to stay on the wound bed, allowing wound healing to continue undisturbed upon dressing removal.^{4-6,12,13}



ALLEVYN ADHESIVE
Foam Dressing



ALLEVYN NON-ADHESIVE
Foam Dressing

ALLEVYN[◇] Ag Antimicrobial Foam Dressing

The silver sulphadiazine antimicrobial impregnated in the foam provides sustained release of silver to the wound bed, and is effective for up to 7 days (in vitro).^{14,15}

- Effective against a broad spectrum of Gram-positive and Gram-negative bacteria, yeast and fungal wound pathogens (in vitro).⁹
- Effective against antibiotic resistant bacteria such as Pseudomonas, MRSA and vancomycin resistant enterococci (VRE).⁹
- Can stay in place for up to 7 days, dependent on wound type and patient exudate levels.^{5,12,16,20}



ALLEVYN Ag Adhesive



ALLEVYN Ag Non-Adhesive



ALLEVYN
Ag Gentle Border


ALLEVYN[◇] GENTLE BORDER Foam Dressing

Versatile, patient-centric design helps you by caring for your patient^{1,2}

Breathable top film to release moisture as needed to create a moist wound healing environment for optimum wound healing⁴⁻⁷


Hydrocellular foam core pad to absorb exudate³

Wound contact layer with **soft silicone adhesive** for easy application and minimal pain and trauma for the patient on removal⁴



ALLEVYN[®] Life Foam Dressing

With its unique quadrilobe shape, wide borders and flexible five layers, the ALLEVYN[®] LIFE mode of action is designed to help patients **get back to their real lives**.^{3,8}



DURAFIBER[®] Gelling Fibre Dressing

- Highly absorbent¹
- Retains/locks in fluid, even under compression
- Minimises risk of pooling^{1-3,6}
- Reduces dead space where bacteria may proliferate^{7,8}
- Conforms intimately to the wound bed^{5,7}
- Soft and highly conformable^{4,5}
- Intact, one-piece removal⁵
- Can be left in place for up to seven days



PICO^o Single Use Negative Pressure Wound Therapy System


PICO 7

*Pump duration 7 days



PICO 14

*Pump duration 14 days



Anatomy of dressing


PICO multi-function dressings² provide you and your patients with the benefits of a gentle,³ absorbent² and evaporative² dressing that has also been engineered to ensure effective negative pressure² is delivered on to the wound.

Absorption^{2*}

20% Approximately 20% fluid still remains in the dressing

Evaporation^{2*}

80% On average 80% of the exudate is lost by evaporation



RENASYS[◇] TOUCH Negative Pressure Wound Therapy System

- Intuitive, user-friendly touchscreen interface for quick, easy-to-learn operation^{1,2}
- Clinically effective for a range of chronic and acute wounds across a variety of care settings³
- Adjustable compression rate and variable intermittent mode allow for tailoring the therapy to an individual patient's needs and comfort²
- The leak gauge is designed to aid clinicians in locating and resolving air leaks²
- Easy-to-use onscreen quick reference guide supports device operation^{2,4}
- Detailed pump activity log enables monitoring of patient concordance
- Up to 14 hours of battery life on a single charge⁵ pressure evenly across whole wound bed²



RENASYS[◇] GO Negative Pressure Wound Therapy System

RENASYS GO is indicated for patients who would benefit from a suction device (negative pressure wound therapy) as it may promote healing via removal of wound exudate¹

- Kits with Soft Port, -G Gauze Dressing Kits with Soft Port and all Drain Kits
- Key lock function which locks the device after 10 minutes to restrict accidental adjustment of therapy
- Compatible with RENASYS dressings kits: -F Foam Dressing
- Continuous and intermittent settings



RENASYS[◇] EZ MAX Negative Pressure Wound Therapy System

RENASYS EZ MAX is indicated for patients who would benefit from a suction device (negative pressure wound therapy) as it may promote healing via removal of wound exudate⁷

- Two canister size options available 800ml and 250ml
- Incorporates a user-friendly display for quick and easy operation
- Allows the clinician to lock the prescribed pressure setting to prevent unintentional or accidental changes
- Compatible with all RENASYS dressings kits; -F Foam Dressing Kits with Soft Port, -G Gauze Dressing Kits with Soft Port, AB Abdominal Dressing Kit with Soft Port and Drain Kits
- Continuous and intermittent. Intermittent mode the pump cycles ON for approx 5 minutes and OFF for 2 minutes (no vacuum)



Smith+Nephew Pte Ltd
ALICE @ Mediapolis
29 Media Circle, #06-05
Singapore 138565
T +65 6270 0552
F +65 6272 6698

www.smith-nephew.com

◆ Trademark of Smith+Nephew
All Trademarks acknowledged
AWM APAC-AWC-33623

Smith+Nephew does not provide medical advice. The information presented is not intended to serve as, medical advice. For detailed device information, including indications for use, contraindications, precautions and warnings, please consult the product's Instructions for Use (IFU) prior to use. It is the responsibility of healthcare professionals to determine and utilise the appropriate products and techniques according to their own clinical judgment for each of their patients.

Intrasite pg 7 References: 1. Colin D, Kurring P, Quinlan D, Yvon C. The clinical investigation of an amorphous hydrogel compared with a dextranomer paste dressing in the management of sloughy pressure injuries. Proceedings of the 5th European conference on advances in wound management, Harrogate, UK, November 1995. 2. Flanagan M. The efficacy of a hydrogel in the treatment of wounds with Non-viable tissue. *Journal of Wound Care*, 1995 Vol 4(6), 264-267. 3. Spooner R. Managing a patients multiple pressure sores. *Journal of Wound Care* (1993), 2(3), 139-141. 4. Ricci E, et al. INTRASITE Gel: indications and results in the therapy of Decubitus Ulcers. Personal Communication 1993. 5. Thomas S. The role of moist wound healing in the management of meningococcal skin lesions: a case study. *World Wide Wounds*, June 1999. 6. Young T, Williams C, Benbow M, et al. A study of two hydrogels used in the management of pressure sores. 103-106. 7. Bale S, Banks V, Haglestein S, et al. A comparison of two amorphous hydrogels in the debridement of pressure sores. *Journal of Wound Care* 1998; 7 (2): 65-68. 8. Coates TJ, et al. The effect of gel burns dressings on skin temperature. *Emergency Medicine Journal*, 2002; 19:224-225. 9. Thomas S, Rowe H, Keats J, Morgan R. The management of extravasation injury in neonates. *The Pharmaceutical Journal* 1987;239: 584. 10. Ricci E, Cassino R, Secreto P. Treatment of necrotic tissue with INTRASITE gel. 11. Regan M. The use of INTRASITE Gel in healing open sternal wounds. *Ostomy/Wound Management*, *Journal for Extended Patient Care Management*, Volume 38, No. 3, April 1992. 12. Flanagan M. The use of a Modified Formulation of an Amorphous Hydrogel Containing Cross-linked Carboxy Methyl Cellulose (CMC) Polymer in the Management of Wounds that Present with Non-viable Tissue - A Multi-centre Clinical Trial. 13. Westerhof W, Mekkes JR. A pilot study comparing INTRASITE Gel with saline soaked gauze for debridement, Ref CTR90/08 by D Myers. 14. Colin D, Kurring P, Quinlan D, Yvon C. Managing sloughy pressure sores. *Journal of Wound Care*, 1996 Vol 5(10), 444-446. 15. Thomas S, Fear M. The efficacy of INTRASITE Gel as a debrider of nonviable tissue from wounds treated in the community. Poster presentation at the European Wound Management Conference, Harrogate 1993. 16. Pastre L, Wetzberger S, Andriessen A. INTRASITE Gel as a desloughing agent in the management of patients with wounds requiring debridement in the community setting. 17. De Vincentis G, Caracciolo G, Anselmi A. INTRASITE Gel in the management of deep second and third degree burns in children [Poster] 1996. [Poster] 1995. 18. Thomas S, Rowe HN, et al. A new approach to the management of extravasation injury in neonates. *The Pharmaceutical Journal* (1987) Nov: 584-585. 19. Ratliff CR. INTRASITE Gel to promote wound healing from necrosis. *The Cancer Bulletin* 1991; 43 (1): 85-6. 20. Gates JL, Holloway GA. A comparison of wound environments. A moist wound environment dressing system versus the traditional normal saline wet-to-dry dressing. *Ostomy/Wound Management* 1992; 38 (8): 35-37. 21. Boardman M, Mellor K, Neville B. Treating a patient with a heavily exuding malodorous fungating ulcer. *Journal of Wound Care*. 1993 1993;2(2): 74-6. 22. Van Look R, Verbiest A. The treatment of complicated and infected wounds [Poster] 1993. 36. Riggs R, Bale S. Management of necrotic wounds as a complication of histiocytosis X. *Journal of Wound Care*. 1993 1993;2(5):260-1. 23. Mitchell E. Keeping leg ulcers moist. *Nurs Times*. 1990 9/19/1990;86(38):67-8. 24. Benbow M, Pearce C. The care of an infant with homozygous protein C deficiency. *Journal of Wound Care*. 1994 1994;3(1):21-4. 25. Hollinworth H. Managing a patient with an infected foot ulcer. *Journal of Wound Care*. 1993 1993;2(1):22-6. 26. Meier L. Treatment of a patient with an amputation above the left knee [Poster] 1994. 27. Todd M. The use of an amorphous hydrogel in the management of granulating wounds. Poster at Woundcare Society Meeting, Harrogate, UK, November 1994. 28. Ricci E, Barberid S, Ferraris S, Anselmetti G. The treatment of fistulae with INTRASITE Gel; Interim results [Poster] 1993. 29. Cassino R, Ricci E, Carusone A. Management of heavily exuding wounds requiring debridement [Poster] 1997. 30. Gethin G, Cowman S. Manuka Honey vs. Hydrogel—a prospective, open label, multicenter, randomized controlled trial to compare desloughing efficacy and healing outcomes in venous ulcers. *J Clin Nurs*. 2009 2/2009;18(3):466-74.

Versajet pg 7 References: 1. Granick MS et al, "Efficacy and cost-effectiveness of a high-powered parallel waterjet for wound debridement", *Wound Repair & Regeneration*, 2006, 14, 394-397. 2. Granick MS et al, "Toward a common language: surgical wound bed preparation and debridement", *Wound Repair & Regeneration*, 2006, 14, S1-S10. 3. Cubison CS et al, "Dermal preservation using the Versajet hydroxyjet system for debridement of pediatric burns", *Burns*, 2006, 32, 714-720. 4. Chammas MF, Gurunluoglu R, Carlsen SN, et al. Surgical debridement of mineral pitch and nonviable penile tissue using water-jet power: a preliminary report. *BJU International* 2008;103(7):974-976. 5. Vanwijck R, Kaba L, Boland S, et al. Immediate skin grafting of sub-acute and chronic wounds debrided by hydroxyjet. *Journal of Plastic, Reconstructive & Aesthetic Surgery*. 2010;63:544-549.

ACTICOAT pg 8 References: 1. Skog E, Arnesjo B, Troeng T, et al. A randomised trial comparing cadexomer iodine and standard treatment in the outpatient management of chronic venous ulcers. *Br J Dermatology* (1983) 109, p77-83. 2. Sundberg J, Meller R. A retrospective review of the use of cadexomer iodine in the treatment of chronic wounds. *Wounds* (1997) 9(3), p68-86. 3. Troeng T, Skog E, Arnesjo B, et al. In Cadexomer Iodine, Fox JA, Fischer H (eds) (1983) p43-50. 4. Holloway GA, Johansen KH, Barnes RW, et al. Multicenter trial of cadexomer iodine to treat venous stasis ulcer. *West J Med* (1989, Jul) 151, p35-38. 5. Ormiston MC, Seymour MTJ, Venn GE, et al. A randomised comparison of cadexomer iodine and a standard treatment in out-patients with chronic leg ulcers. In *Cadexomer Iodine*, Fox JA, Fischer H (eds) (1983) p63-69. 6. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. *Int J Dermatology* (1998) 37, p390-396. 7. Moberg S, Hoffman L, Grenner M, et al. A randomised trial of cadexomer iodine in decubitus ulcers. *J Am Geriatrics Soc* (1983) 31, p462-465. 8. Lindsay G, Latta D, Lyons KGB, et al. A study in general practice of the efficacy of cadexomer iodine in venous leg ulcers treated on alternate days. *Acta Therapeutica* (1986) 12, p141-148. 9. Johnson A. A combative healer with no ill effect. *Iodosorb* in the treatment of infected wounds. *Professional Nurse* (Oct 1991) p60-64.

IODOORB pg 8 References: 1. Skog E, Arnesjo B, Troeng T, et al. A randomised trial comparing cadexomer iodine and standard treatment in the outpatient management of chronic venous ulcers. *Br J Dermatology* (1983) 109, p77-83. 2. Sundberg J, Meller R. A retrospective review of the use of cadexomer iodine in the treatment of chronic wounds. *Wounds* (1997) 9(3), p68-86. 3. Troeng T, Skog E, Arnesjo B, et al. In Cadexomer Iodine, Fox JA, Fischer H (eds) (1983) p43-50. 4. Holloway GA, Johansen KH, Barnes RW, et al. Multicenter trial of cadexomer iodine to treat venous stasis ulcer. *West J Med* (1989, Jul) 151, p35-38. 5. Ormiston MC, Seymour MTJ, Venn GE, et al. A randomised comparison of cadexomer iodine and a standard treatment in out-patients with chronic leg ulcers. In *Cadexomer Iodine*, Fox JA, Fischer H (eds) (1983) p63-69. 6. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. *Int J Dermatology* (1998) 37, p390-396. 7. Moberg S, Hoffman L, Grenner M, et al. A randomised trial of cadexomer iodine in decubitus ulcers. *J Am Geriatrics Soc* (1983) 31, p462-465. 8. Lindsay G, Latta D, Lyons KGB, et al. A study in general practice of the efficacy of cadexomer iodine in venous leg ulcers treated on alternate days. *Acta Therapeutica* (1986) 12, p141-148. 9. Johnson A. A combative healer with no ill effect. *IODOORB* in the treatment of infected wounds. *Professional Nurse* (Oct 1991) p60-64.

IODOFLEX pg 8 References: 1. Roche ED, Woodmansey EJ, Yang Q, et al. Cadexomer iodine effectively reduces bacterial biofilm in porcine wounds ex vivo and in vivo. *Int Wound J*. 2019;1-10 [in press]. 2. Akiyama H, Oono T, Saito M, Iwatsuki K. Assessment of Cadexomer Iodine against *Staphylococcus aureus* Biofilm In vivo and In vitro Using Confocal Laser Scanning Microscopy. *The Journal of Dermatology*. 2004;31:529-534. 3. Fitzgerald DJ, Renick PJ, Forrest EC, et al. Cadexomer iodine provides superior efficacy against bacterial wound biofilms in vitro and in vivo. *Wound Repair Regen*. 2017;25(1):13-24. 4. Phillips PL, Yang Q, Davis S, et al. Antimicrobial dressing efficacy against mature *Pseudomonas aeruginosa* biofilm on porcine skin explants. *Int Wound J*. 2015;12(4):469-483. 5. Oates JL, Phillips CD, Wolcott R, Woodmansey E. Effect of a Cadexomer Iodine Wound Dressing on a Chronic Wound Model Multi-Species Biofilm Model with Comparison to a Silver Hydrofiber Antibiofilm Dressing. 2016. 6. Hill KE, Malic S, McKee R, et al. An in vitro model of chronic wound biofilms to test wound dressings and assess antimicrobial susceptibilities. *J Antimicrob Chemother*. 2010;65(6):1195-1206. 7. Kiamco MM, Atci E, Mohamed A, Call DR, Beyenal H. Hyperosmotic Agents and Antibiotics Affect Dissolved Oxygen and pH Concentration Gradients in *Staphylococcus aureus* Biofilms. *Appl Environ Microbiol*. 2017;83(6). 8. Ormiston MC, Seymour MTJ, Venn GE, Cohen RI, Fox JA. Controlled trial of Iodosorb in chronic venous ulcers. *British Medical Journal*. 1985;291:308-310. 9. Hansson C, Persson L-M, Stenquist B, et al. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. *International Journal of Dermatology*. 1998;37(390-396). 10. Troeng T, Skog E, Arnesjo B, et al. A Randomised Multicentre Trial to Compare the Efficacy of Cadexomer Iodine and Standard Treatment in the Management of Chronic Venous Ulcers in Out-Patients. Stuttgart: Schattauer Verlag; 1983. 11. Skog E, Arnesjo B, Troeng T, et al. A randomized trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers. *British Journal of Dermatology*. 1983;109:77-83. 12. Smith+Nephew data on file 2009; #09110113. Gottardi W. Disinfection, sterilization and preservation (ed. Block, S. S.) 152-166 (Lea and Febiger, 1991). 14. Cooper RA. Iodine revisited. *Int Wound J*. 4, 124-37 (2007). 15. Johnson A. A combative healer with no ill-effect Iodosorb in the treatment of infected wounds. *Prof. Nurse* 7, 60, 62, 64 (1991).

ALLEVYN & ALLEVYN Ag pg 9 References: 1. Buzza K. Evidence outcomes report. EO.AWM.PCSgen.001.v2. 2019. 2. Data on File Reference 0702002, ALLEVYN Ag adhesive dressing physical properties, Daubney L, February 2007. 3. The clinical and physical properties of ALLEVYN Ag adhesive dressings and the moist wound environment. 4. Avanzi R, Martinelli R, Accardi S, et al. Adhesive hydrocolloidal dressing vs. hydrocolloid dressing in the treatment of 2nd and 3rd degree pressure ulcers. 5. Quinlan D, et al. A multi-centre pilot study to investigate the physical performance of a novel ALLEVYN adhesive dressing. Smith & Nephew Clinical Trial Report SR/000000/CT9336. 6. Reali, Martini, Borgognoni, Andriessen A. An adhesive hydrocolloidal dressing in the treatment of partial thickness skin graft donor sites. In EWMA; 1997; Milan; 1997. 7. Harding KG, Bale S. A randomised clinical study to evaluate and compare the performance of ALLEVYN adhesive and Tielle dressings in the management of exuding wounds in the community. Smith & Nephew Healthcare. 8. Cassino R, Ricci E, Carusone A, et al. A conformable hydrogel in the debridement of complex necrotic wounds. In: EWMA; 1997; Milan; 1997. 9. Data on File 0703007 - Antimicrobial activity of ALLEVYN Ag adhesive dressing against a broad spectrum of microorganisms, Emma Woodmansey, March 2007. 10. Data on File 0707052 - Antimicrobial activity of ALLEVYN Ag adhesive dressing against a broad spectrum of wound pathogens using a dynamic shake flask. Kirsten Driffield, July 2007. 11. Data on File 0703014 - Bacterial barrier testing (wet-wet) on samples of ALLEVYN Ag adhesive dressing with a 7 day test duration against MRSA, Emma Woodmansey, March 2007. 12. Bale S, Squires D, Yarnon T, et al. A comparison of two dressings in pressure sore management. *J Wound Care* 1997;6(10):463-466. 13. Cassino R, Ricci E, Carusone A, et al. Management of heavily exuding wounds requiring debridement. In: EWMA; 1997; Milan; 1997. 14. Data on File 0703014 - Antimicrobial activity of ALLEVYN Ag adhesive over 7 days, Emma Woodmansey, March 2007. 15. Data on File Report 0703009 - ALLEVYN Ag adhesive dressing silver release testing. Daubney L, March 2007. 16. Mole T. Internal Memo - CT0336. Analysis of dressing performance at the sacrum location. 17. Laboratory Report No: AA400579 - (1) Comparison of old and new formulae for Cutinova Thin. (2) Evaluation of the transferability of the results from (1) to formulae with the same polymer raw material components. (3) Evaluation of transferability of the results of the old products to the new products with modified formula. 18. Wunscher MJ. Clinical Evaluation of CUTINOVA™ Thin. 19. Based on assumption that the semi permeable backing film of each dressing family, functions in manner comparable to semi permeable backing films, e.g. OPSITE™. 20. ALLEVYN Ag adhesive dressings: A summary of absorbent capacity and antimicrobial longevity.

ALLEVYN GENTLE BORDER pg 9 References: 1. Vowden K, et al. An open, prospective randomised, multi-centre clinical evaluation of a hydrocolloidal silicone foam dressing in the management of exuding chronic and acute wounds. Poster presented at EWMA 2011. 2. Callaghan R, et al. Case series evaluation: The use of ALLEVYN Gentle Border Multisite on chronic wounds. *Wounds UK* 2012;8(4). 3. Smith & Nephew data on file report DS/09/013/R2. Daubney L, May 2009. 4. Hurd T, et al. A multi-centre in-market evaluation of ALLEVYN Gentle Border. *Wounds UK* 2009;5(3):32-44. 5. Smith+Nephew 2016. ALLEVYN Gentle Border Heel Gen 2 - physical evaluation. Internal Report. DS/16/465/R. 6. Smith+Nephew 2017. ALLEVYN Gentle Border Gen 2 - Physical Evaluation. Internal Report. DS/16/424/R V3. 7. Smith+Nephew 2019. Use of Moisture Vapour Permeability (MVP) and Moisture Vapour Transmission Rate (MVTR) data to support product claims referring to moist wound healing. Internal report. EO.AWM.PCSgen.001.v2

ALLEVYN Life Dressings pg 10 References: 1. Joy H, Bielby A, Searle R. A collaborative report to enhance efficiency through dressing change practice. *Journal of wound care*. 2015;24(7):312, 314-317. n=37; when used with appropriate training, education and promotion of practice change. 3. Smith & Nephew May 2016. New ALLEVYN Life Gen2 wcl - Physical Testing. Internal Report. DS/15/025/R 4. Viamontes L, Jones A.M., Evaluation study of the properties of two adhesive foam dressings. *British Journal of Nursing (Tissue Viability Supplement)*. 2003;12(11):S43-S49. 5. Stephen-Haynes J, Bielby A, Searle R. The clinical performance of a silicone foam in an NHS community trust. *Journal of Community Nursing*. 2013;27(5):50-59. 6. Smith & Nephew February 2016. Subjective comparison of masking ability of the New ALLEVYN LIFE versus Current ALLEVYN LIFE by Healthcare Professionals. Internal Report. DS/16/061/R. 8. Rossington A, Drysdale K, and Winter R. Clinical performance and positive impact on patient wellbeing of ALLEVYN LIFE. *Wounds UK*. 2013;9(4):91-95. 10. Hurd T, Gregory L, Jones A, Brown S. A multi-centre in-market evaluation of ALLEVYN Gentle Border. *Wounds UK*. 2009;5(3):32-44. 18. Smith & Nephew 2016. Product Performance of Next Generation ALLEVYN LIFE (HVT080). Internal Report. GMCA-DOF/08. 19. Krönert G, Roth H, and Searle R. Efficiency in wound care: The impact of introducing a new foam dressing in community practice. EWMA Journal. 2016;16(2):7-12. 20. Vowden K, Molemen N, Drysdale K, Mistry C. An open, prospective randomised, multi-centre clinical evaluation of a hydrocolloidal silicone foam dressing in the management of exuding chronic and acute wounds. Paper presented at: EWMA; 2011; Brussels. 21. Matsumura H, Imai R, Ahmatjan N, et al. Removal of adhesive wound dressing and its effects on the stratum corneum of the skin: comparison of eight different adhesive wound dressings. *Int Wound J*. 2014;11(1):50-54. 22. Smith & Nephew 2012. Simulated Model Testing of ALLEVYN LIFE and Mepilex Border. Internal Report. DS/12/130/DOF. 23. Smith & Nephew, February 2016. New ALLEVYN LIFE Pad Performance Size. Internal Report. DS/16/062/R.

DURAFIBER pg 10 References: 1. Dowler A. DURAFIBER Dressing physical properties. Laboratory report DS/10/056/R1 05 2010. 2. Dowler A. Testing of absorption of DURAFIBER and Aquacel® while the dressing is under compression. Analytical report DS/10/037/R1 03 2010. 3. Dowler A. Report of testing on lateral wicking of DURAFIBER versus Aquacel® and Quikstat® dressings. Analytical report DS/10/042/R1 04 2010. 4. Demonstrable S, Barrett S, et al. Case series evaluation: The use of DURAFIBER on exuding wounds. *Wounds UK* 2012, Vol 8, No 3. 6. Lumb H. Visual demonstration of sequestration of *Pseudomonas aeruginosa* and *Staphylococcus aureus* in a DURAFIBER Dressing using confocal microscopy. Data on file report - 1004001 04 2010. 7. Dowler A. Testing performed as part of DURAFIBER photo shoot. October 2011. Laboratory report DS/11/187/DOF. 8. Woodmansey E. The potential for proliferation of bacteria in wound exudate. RR-WMPO6290-40-01 04 2010.

PICO 7 pg 11 References: 1. Lumb H. Data on file report. 1102010. April 2011. 2. Malmjö M, Huddleston EM, Martin R. Biological Effects of a Disposable, Canisterless Negative Pressure Wound Therapy System. *Eplasty* 2014;14:e15 PICO 7. 3. Hurd T, Gregory H, Jones A, Brown S. A multicentre in-market evaluation of ALLEVYN Gentle Border. *Wounds UK* 2009, Vol 5, No 3. 4. Data on file reference DS/11/037/R2 - In-vitro wound model testing of PICO at a moderate exudate flow rate. Sarah Roberts, March 2011 (In-vitro). 5. Data on file reference DS/11/057/R2 - In-vitro wound model testing of PICO at a low exudate flow rate. Sarah Roberts, April 2011 (In-vitro).

RENASYS TOUCH pg 12 References: 1. Smith+Nephew 2016. Smith+Nephew's RENASYS Touch Device - User Validation. Internal Report. DS/16/174/R. 2. Forlee M, Richardson J. An interim analysis of device functionality and usability of RENASYS TOUCH - a new off-the-shelf Negative Pressure Wound Therapy (NPWT) system. Paper presented at Wounds UK 2016. Harrogate, UK. 3. Forlee M, Van Zyl L, Louw H, Nel J, Fourie N, Hartley R. A randomised controlled trial to compare the clinical efficacy and acceptability of adjustable intermittent and continuous Negative Pressure Wound Therapy (NPWT) in a new portable NPWT system. Paper presented at EWMA, 2018, Krakow, Poland. 4. Smith+Nephew 2016. Smith+Nephew's RENASYS Touch Device Features - Software features. Internal Report. DS.16.179.R. 5. Smith+Nephew 2018. Project Colne Verification of RENASYS TOUCH Connect device battery while in use. 21. DS.17.623.R V2. 6. Birke-Sorensen H, et al. Evidence-based recommendations for Negative Pressure Wound Therapy: treatment variables (pressure levels, wound filler and contact layer) - steps towards an international consensus. *J Plast Reconstr Aesthet Surg*. Sep 2011;64:51-516. 7. Birke-Sorensen H, et al. Evidence-based recommendations for Negative Pressure Wound Therapy: treatment variables (pressure levels, wound filler and contact layer) - steps towards an international consensus. *J Plast Reconstr Aesthet Surg*. Sep 2011;64:51-516.